About
Proprietary fluorescent tracer agents and transdermal detection systems
Areas of Focus
Categories
Medical Measurement
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
839
By Phase
EARLY_PHASE1: 2PHASE1: 3PHASE3: 3NA: 1PHASE2: 1
By Status
COMPLETED: 8NOT_YET_RECRUITING: 2
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT04008121Lead Sponsor
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
EARLY_PHASE1Not yet recruiting
10 participants
Started: Nov 30, 2025 · Completed: May 31, 2026
NCT07080008Lead Sponsor
Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
PHASE1Not yet recruiting
10 participants
Started: Aug 31, 2025 · Completed: Jan 31, 2026
NCT05777174Lead Sponsor
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
PHASE3Completed
149 participants
Started: Mar 20, 2023 · Completed: Apr 15, 2024
NCT05943977Collaborator
A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
PHASE3Completed
121 participants
Started: Mar 2, 2023 · Completed: Nov 30, 2023
NCT05425719Lead Sponsor
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
PHASE3Completed
249 participants
Started: Jun 14, 2022 · Completed: Feb 15, 2023
Locations (1)
Headquarters
Mannheim, Germany
Map
Loading map...